Titre : Histone-lysine N-methyltransferase

Histone-lysine N-methyltransferase : Questions médicales fréquentes

Termes MeSH sélectionnés :

Microarray Analysis
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Histone-lysine N-methyltransferase : Questions médicales les plus fréquentes", "headline": "Histone-lysine N-methyltransferase : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Histone-lysine N-methyltransferase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-29", "dateModified": "2025-04-23", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Histone-lysine N-methyltransferase" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Histone méthyltransférases", "url": "https://questionsmedicales.fr/mesh/D000076983", "about": { "@type": "MedicalCondition", "name": "Histone méthyltransférases", "code": { "@type": "MedicalCode", "code": "D000076983", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.913.555.500.800.200" } } }, "about": { "@type": "MedicalCondition", "name": "Histone-lysine N-methyltransferase", "alternateName": "Histone-Lysine N-Methyltransferase", "code": { "@type": "MedicalCode", "code": "D011495", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Jasmin Mecinović", "url": "https://questionsmedicales.fr/author/Jasmin%20Mecinovi%C4%87", "affiliation": { "@type": "Organization", "name": "Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ, Nijmegen, The Netherlands." } }, { "@type": "Person", "name": "Abbas H K Al Temimi", "url": "https://questionsmedicales.fr/author/Abbas%20H%20K%20Al%20Temimi", "affiliation": { "@type": "Organization", "name": "Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ, Nijmegen, The Netherlands." } }, { "@type": "Person", "name": "Danny C Lenstra", "url": "https://questionsmedicales.fr/author/Danny%20C%20Lenstra", "affiliation": { "@type": "Organization", "name": "Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ, Nijmegen, The Netherlands." } }, { "@type": "Person", "name": "Paul B White", "url": "https://questionsmedicales.fr/author/Paul%20B%20White", "affiliation": { "@type": "Organization", "name": "Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands. Floris.Rutjes@ru.nl." } }, { "@type": "Person", "name": "Ping Qian", "url": "https://questionsmedicales.fr/author/Ping%20Qian", "affiliation": { "@type": "Organization", "name": "Chemistry and Material Science Faculty, Shandong Agricultural University, Daizong Road No.61, Tai'an, 271018, P.R. China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Prenatal diagnosis of fetuses conceived by assisted reproductive technology by karyotyping and chromosomal microarray analysis.", "datePublished": "2023-01-17", "url": "https://questionsmedicales.fr/article/36684682", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.7717/peerj.14678" } }, { "@type": "ScholarlyArticle", "name": "Chromosome microarray analysis combined with karyotype analysis is a powerful tool for the detection in pregnant women with high-risk indicators.", "datePublished": "2023-11-11", "url": "https://questionsmedicales.fr/article/37951870", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12884-023-06052-z" } }, { "@type": "ScholarlyArticle", "name": "Saliva DNA: An alternative biospecimen for single nucleotide polymorphism chromosomal microarray analysis in autism.", "datePublished": "2023-09-15", "url": "https://questionsmedicales.fr/article/37715344", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/ajmg.a.63400" } }, { "@type": "ScholarlyArticle", "name": "Fetal congenital gastrointestinal obstruction: prenatal diagnosis of chromosome microarray analysis and pregnancy outcomes.", "datePublished": "2023-07-08", "url": "https://questionsmedicales.fr/article/37422671", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12884-023-05828-7" } }, { "@type": "ScholarlyArticle", "name": "Genetic causes of isolated and severe fetal growth restriction in normal chromosomal microarray analysis.", "datePublished": "2023-01-02", "url": "https://questionsmedicales.fr/article/36495297", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/ijgo.14620" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Enzymes et coenzymes", "item": "https://questionsmedicales.fr/mesh/D045762" }, { "@type": "ListItem", "position": 3, "name": "Enzymes", "item": "https://questionsmedicales.fr/mesh/D004798" }, { "@type": "ListItem", "position": 4, "name": "Transferases", "item": "https://questionsmedicales.fr/mesh/D014166" }, { "@type": "ListItem", "position": 5, "name": "One-carbon group transferases", "item": "https://questionsmedicales.fr/mesh/D019875" }, { "@type": "ListItem", "position": 6, "name": "Methyltransferases", "item": "https://questionsmedicales.fr/mesh/D008780" }, { "@type": "ListItem", "position": 7, "name": "Protein Methyltransferases", "item": "https://questionsmedicales.fr/mesh/D011496" }, { "@type": "ListItem", "position": 8, "name": "Histone méthyltransférases", "item": "https://questionsmedicales.fr/mesh/D000076983" }, { "@type": "ListItem", "position": 9, "name": "Histone-lysine N-methyltransferase", "item": "https://questionsmedicales.fr/mesh/D011495" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Histone-lysine N-methyltransferase - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Histone-lysine N-methyltransferase", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-13", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Histone-lysine N-methyltransferase", "description": "Comment diagnostiquer une dysfonction des N-méthyltransférases ?\nQuels tests sont utilisés pour évaluer l'activité des N-méthyltransférases ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nQuels marqueurs biologiques sont associés aux N-méthyltransférases ?\nPeut-on utiliser l'imagerie pour diagnostiquer des anomalies ?", "url": "https://questionsmedicales.fr/mesh/D011495?mesh_terms=Microarray+Analysis&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Histone-lysine N-methyltransferase", "description": "Quels symptômes sont liés à une dysfonction des N-méthyltransférases ?\nLes symptômes sont-ils spécifiques à une maladie ?\nY a-t-il des symptômes neurologiques associés ?\nLes symptômes peuvent-ils évoluer avec le temps ?\nLes symptômes sont-ils visibles à l'examen physique ?", "url": "https://questionsmedicales.fr/mesh/D011495?mesh_terms=Microarray+Analysis&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Histone-lysine N-methyltransferase", "description": "Peut-on prévenir les dysfonctionnements des N-méthyltransférases ?\nY a-t-il des facteurs environnementaux à éviter ?\nLes dépistages réguliers sont-ils recommandés ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLes exercices physiques aident-ils à prévenir les dysfonctionnements ?", "url": "https://questionsmedicales.fr/mesh/D011495?mesh_terms=Microarray+Analysis&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Histone-lysine N-methyltransferase", "description": "Quels traitements ciblent les N-méthyltransférases ?\nLa thérapie génique est-elle une option ?\nLes traitements sont-ils personnalisés ?\nY a-t-il des effets secondaires aux traitements ?\nLes traitements sont-ils efficaces à long terme ?", "url": "https://questionsmedicales.fr/mesh/D011495?mesh_terms=Microarray+Analysis&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Histone-lysine N-methyltransferase", "description": "Quelles complications peuvent survenir avec des dysfonctionnements ?\nLes complications sont-elles réversibles ?\nY a-t-il des complications neurologiques possibles ?\nLes complications affectent-elles la qualité de vie ?\nComment gérer les complications liées aux N-méthyltransférases ?", "url": "https://questionsmedicales.fr/mesh/D011495?mesh_terms=Microarray+Analysis&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Histone-lysine N-methyltransferase", "description": "Quels sont les principaux facteurs de risque ?\nL'âge est-il un facteur de risque ?\nLe mode de vie influence-t-il le risque ?\nLes maladies chroniques sont-elles des facteurs de risque ?\nY a-t-il des facteurs génétiques impliqués ?", "url": "https://questionsmedicales.fr/mesh/D011495?mesh_terms=Microarray+Analysis&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction des N-méthyltransférases ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses d'expression génique peuvent être utilisés." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'activité des N-méthyltransférases ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests biochimiques et des méthodes de chromatographie peuvent être employés." } }, { "@type": "Question", "name": "Les biopsies sont-elles nécessaires pour le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent être nécessaires pour évaluer les modifications épigénétiques." } }, { "@type": "Question", "name": "Quels marqueurs biologiques sont associés aux N-méthyltransférases ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les niveaux de méthylation des histones peuvent servir de marqueurs biologiques." } }, { "@type": "Question", "name": "Peut-on utiliser l'imagerie pour diagnostiquer des anomalies ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie n'est pas couramment utilisée pour diagnostiquer ces anomalies." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une dysfonction des N-méthyltransférases ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles de l'expression génique peuvent entraîner divers symptômes, selon le tissu." } }, { "@type": "Question", "name": "Les symptômes sont-ils spécifiques à une maladie ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Non, ils peuvent varier selon la maladie et le type de tissu affecté." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines dysfonctions peuvent entraîner des troubles neurologiques." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils évoluer avec le temps ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'évolution des symptômes dépend de la progression de la maladie sous-jacente." } }, { "@type": "Question", "name": "Les symptômes sont-ils visibles à l'examen physique ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Souvent, les symptômes ne sont pas visibles et nécessitent des tests spécifiques." } }, { "@type": "Question", "name": "Peut-on prévenir les dysfonctionnements des N-méthyltransférases ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un mode de vie sain peut réduire les risques." } }, { "@type": "Question", "name": "Y a-t-il des facteurs environnementaux à éviter ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains agents chimiques et toxines peuvent influencer la fonction enzymatique." } }, { "@type": "Question", "name": "Les dépistages réguliers sont-ils recommandés ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des dépistages peuvent être utiles pour les personnes à risque génétique élevé." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle dans la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut influencer la santé épigénétique et réduire les risques." } }, { "@type": "Question", "name": "Les exercices physiques aident-ils à prévenir les dysfonctionnements ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut avoir un impact positif sur la santé cellulaire." } }, { "@type": "Question", "name": "Quels traitements ciblent les N-méthyltransférases ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs spécifiques des N-méthyltransférases sont en cours de développement." } }, { "@type": "Question", "name": "La thérapie génique est-elle une option ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la thérapie génique pourrait corriger les anomalies liées aux N-méthyltransférases." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent être adaptés en fonction du profil génétique du patient." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires aux traitements ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, comme tout traitement, des effets secondaires peuvent survenir." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces à long terme ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité à long terme dépend de la maladie et de la réponse individuelle au traitement." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des dysfonctionnements ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications peuvent inclure des cancers et d'autres maladies génétiques." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles." } }, { "@type": "Question", "name": "Y a-t-il des complications neurologiques possibles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles neurologiques peuvent survenir en raison de modifications épigénétiques." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent significativement impacter la qualité de vie des patients." } }, { "@type": "Question", "name": "Comment gérer les complications liées aux N-méthyltransférases ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La gestion nécessite une approche multidisciplinaire et un suivi régulier." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux et l'exposition à des agents environnementaux sont des facteurs clés." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque de dysfonctionnement enzymatique augmente avec l'âge." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie malsain peut augmenter le risque de dysfonctionnement." } }, { "@type": "Question", "name": "Les maladies chroniques sont-elles des facteurs de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines maladies chroniques peuvent prédisposer à des dysfonctionnements enzymatiques." } }, { "@type": "Question", "name": "Y a-t-il des facteurs génétiques impliqués ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des mutations génétiques peuvent augmenter le risque de dysfonctionnement." } } ] } ] }

Sources (10000 au total)

Prenatal diagnosis of fetuses conceived by assisted reproductive technology by karyotyping and chromosomal microarray analysis.

Invasive prenatal evaluation by chromosomal microarray analysis (CMA) and karyotyping might represent an important option in pregnant women, but limited reports have applied CMA and karyotyping of fet... This retrospective study included all singleton fetuses conceived by ART from January 2015 to December 2021. Anomalies prenatally diagnosed based on karyotyping and CMA were analyzed. Prevalence rates... In total, 224 subjects were assessed by karyotyping and CMA. In the examined patients, chromosomal and karyotype abnormality rates were 3.57% (8/224) and 8.93% (20/224), respectively. This finding ind... Prenatal diagnosis including karyotyping and CMA is recommended for fetuses conceived by ART, with or without ultrasound findings....

Chromosome microarray analysis combined with karyotype analysis is a powerful tool for the detection in pregnant women with high-risk indicators.

Karyotype analysis and fluorescence in situ hybridization (FISH) are commonly used for prenatal diagnosis, however they have many disadvantages. Chromosome microarray analysis (CMA) has the potential ... A total of 3336 samples of amniotic fluid or umbilical cord blood from pregnant women with high-risk indicators at our center in southwest of China from June 2018 to January 2023 were included in the ... 3336 samples divided into 2911 cases with single and 425 cases with multiple high-risk indicators. The aneuploidy and pathogenic/likely pathogenic copy number variations (CNVs) of 2911 cases with sing... The combined application of CMA and karyotyping were recommended in prenatal diagnosis for providing a scientific and accurate genetic diagnosis and improving the quality of prenatal genetic counselin...

Fetal congenital gastrointestinal obstruction: prenatal diagnosis of chromosome microarray analysis and pregnancy outcomes.

The aim of this study was to investigate the incidence of chromosome anomalies in different types of congenital gastrointestinal obstruction and assess pregnancy outcomes of fetuses with congenital ga... A total of 64 cases with gastrointestinal obstruction between January 2014 and December 2020 were enrolled in this study. They were divided into three groups according to sonographic images. Group A: ... From January 2014 to December 2020, there were 64 fetus with congenital gastrointestinal obstruction underwent chromosome microarray analysis(CMA), the overall detection rate of CMA testing was 14.1%(... It is crucial to understand whether the gastrointestinal tract abnormality is isolated or associated to other findings. The risk of chromosomal abnormalities in fetuses with isolated lower gastrointes...

Genetic causes of isolated and severe fetal growth restriction in normal chromosomal microarray analysis.

To investigate the genetic burden in fetuses with isolated and severe fetal growth restriction (FGR) using Trio whole-exome sequencing (WES) with a normal chromosomal microarray.... This retrospective study analyzed WES results of singleton fetuses with isolated and severe FGR, whose estimated fetal weight (EFW) was less than the third percentile by Hadlock formula, in a tertiary... Fifty-one fetuses with isolated and severe FGR and negative CMA results underwent Trio-WES. Of all patients, eight (15.7%) were diagnosed with FGR at its early onset (<32 weeks) and showed pathogenic ... The present study indicates that Trio-WES can improve effectivity of prenatal diagnoses for isolated and severe FGR in cases with normal CMA results, aiding prenatal genetic counseling and pregnancy m...

Prenatal diagnosis of chromosomal aberrations by chromosomal microarray analysis and pregnancy outcomes of fetuses with polyhydramnios.

To explore the prenatal clinical utility of chromosome microarray analysis (CMA) for polyhydramnios and evaluate the short and long-term prognosis of fetuses with polyhydramnios.... A total of 600 singleton pregnancies with persistent polyhydramnios from 2014 to 2020 were retrospectively enrolled in this study. All cases received amniocentesis and were subjected to CMA results. A... The detection rates of either aneuploidy or pathogenic copy number variants in fetuses with non-isolated polyhydramnios were significantly higher than those with isolated polyhydramnios (5.0... For low-risk pregnancies, invasive prenatal diagnosis of isolated polyhydramnios might be unnecessary. CMA should be considered for fetuses with structural anomalies. In CMA-negative cases, the progno...

Chromosomal microarray analysis versus noninvasive prenatal testing in fetuses with increased nuchal translucency.

To evaluate if the NT value of 2.5 mm ≤ NT < 3.0 mm is an appropriate indication for CMA tests among fetuses with isolated increased NT and NIPT is more suitable instead.... A total of 442 fetuses with NT ≥ 2.5 mm were included, in which 241 fetuses underwent karyotype. CMA tests were then carried out when cytogenic analysis showed normal chromosomes and CNV status was co... Of the 241 fetuses with NT ≥ 2.5 mm, 47(19.50%) were identified by karyotype with chromosomal abnormalities. Among 194 cases with normal karyotype, CMA unraveled additional CNVs in 16(8.25%) cases, in... While no pathogenic CNVs were detected in fetuses, chromosomal aneuploidies and genomic imbalance were found to be the major type of abnormalities when NT was 2.5-3.0 mm. Therefore, our data suggested...

Integrated multiple-microarray analysis and mendelian randomization to identify novel targets involved in diabetic nephropathy.

Diabetic nephropathy (DN), which is the main cause of renal failure in end-stage renal disease, is becoming a common chronic renal disease worldwide. Mendelian randomization (MR) is a genetic tool tha... Five DN gene expression datasets were selected from the Gene Expression Omnibus. The robust rank aggregation (RRA) method was used to integrate differentially expressed genes (DEGs) of glomerular samp... A total of 82 DEGs (53 upregulated and 29 downregulated) were identified through RRA integrated analysis. The enriched Gene Ontology annotations and Kyoto Encyclopedia of Genes and Genomes pathways of... Our integrated analysis identified novel biomarkers, including MICB and GZMA, which may help further understand the complicated mechanisms of DN and identify new target pathways for intervention....